Search research articles
Contact Us
Filters
Showing results (51-60 of 126) with videos related to
Page
of 13
Sort By:
Plos One
|
January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer
Sherene Loi, Stefan Michiels, Jose Baselga, et al.
Plos One
|
April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
Sherene Loi, Stefan Michiels, Jose Baselga, et al.
International Journal of Cancer
|
January 30, 2019
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Ofra Novoplansky, Matthew Fury, Manu Prasad, et al.
Breast Cancer Research and Treatment
|
December 29, 2015
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience
Otto Metzger-Filho, Evandro de Azambuja, Marion Procter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2005
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study
Brian Leyland-Jones, Vladimir Semiglazov, Marek Pawlicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2014
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases
Josep Tabernero, Maria Elena Elez, Maria Herranz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
Elizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
The Lancet. Oncology
|
November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A Bonner, Paul M Harari, Jordi Giralt, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 126) with videos related to
Sort By:
Page
of 13
Plos One
|
January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer
Sherene Loi, Stefan Michiels, Jose Baselga, et al.
Plos One
|
April 24, 2019
Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
Sherene Loi, Stefan Michiels, Jose Baselga, et al.
International Journal of Cancer
|
January 30, 2019
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Ofra Novoplansky, Matthew Fury, Manu Prasad, et al.
Breast Cancer Research and Treatment
|
December 29, 2015
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience
Otto Metzger-Filho, Evandro de Azambuja, Marion Procter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2005
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study
Brian Leyland-Jones, Vladimir Semiglazov, Marek Pawlicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
Roy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2014
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases
Josep Tabernero, Maria Elena Elez, Maria Herranz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
Elizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, et al.
The Lancet. Oncology
|
November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A Bonner, Paul M Harari, Jordi Giralt, et al.
Page
of 13